[1] | Deters LA, Kim E D. Benign Prostatic Hypertrophy HYPERLINK "http://emedicine.medscape.com/article/437359".2015; accessed: October 15, 2015. |
[2] | Seftel AD, Rosen RC, Rosenberg MT, Sadovsky R. Benign prostatic hyperplasia evaluation, treatment and association with sexual dysfunction: practice patterns according to physician specialty. Int J ClinPract. 2008 Apr. 62(4):614-22. [Medline]. |
[3] | [Guideline] American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). American Urological Association. Available at https://www.auanet.org/education/guidelines/benign-prostatic-hyperplasia.cfm. 2014; Accessed: July 24, 2015. |
[4] | McConnell J D, Barry M J, Bruskewitz R C, et al. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline. No. 8, AHCPR Publication No. 94-0582. Rockville, Md: Agency for Healthcare Policy and Research,. Public Health Service, US Department of Health and Human Services, 1994. |
[5] | Bosch J L H R, Hop W C J, Kirkels W J and Schröder FH. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol. 1995 May; 75(5): 622-30. |
[6] | Veselya S, Knutsona T, Dambera JE, Dicuioa M and Dahlstranda C. Relationship between Age, Prostate Volume, Prostate-specific Antigen, Symptom Score and Uroflowmetry in Men with Lower Urinary Tract Symptoms. Department of Urology, Sahlgrenska University Hospital, Göteborg, Swerden. Scandinavian Journal of Urology and Nephrology 2003 Jan; 37(4): 322-8. Source: PubMed. |
[7] | Hedelina H, Johanssona N and Ströberga P. Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine. Scand J UrolNephrol. 2005; 39(2): 154-9. |
[8] | Tsukamoto T, Masumori N, Rahman M and Crane M M. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally. Int J Urol. 2007 April; 14(4): 321-4. |
[9] | Masumori N, Tanaka Y, Takahashi A, Itoh N, Ogura H, Furuya S, Tsukamoto T. Lower urinary tract symptoms of men seeking medical care comparison of symptoms found in the clinical setting and in a community study. Urology. 2003 August; 62(2): 266-72. |
[10] | Martin SA, Haren MT, Marshall VR, Lange K, Wittert GA. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol 2011; 29: 179–84. |
[11] | Kupelian V, Wei JT, O’Leary MP, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med 2006; 166: 2381–7. |
[12] | Taub DA, Wei JT. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. CurrUrol Rep 2006; 7: 272–81. |
[13] | Battikhi M N G, Hussein I. Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk, International Urology and Nephrology 2006 December; 38(3-4): 559-564. |
[14] | Bryant R J, Lilja H. Emerging PSA-Based Tests to Improve Screening, Urologic Clinics of North America 2014; 41(2): 267. |
[15] | Murphy D. The Melbourne Consensus Statement on Prostate Cancer Testing. 2013 [cited 24th November 2013]. Available at: https://0x9.me/21zIY. Accessed July 14, 2017. |
[16] | Espaldon R, Kirby K A, Fung K Z., Freedland, S J, Walter L C. Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold. Urology. .2014 March; 83(3): 599-605. |
[17] | Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs F D R, Fourcade R, Kiemeney K, Lee C. The prevalence of lower urinary tract symptoms in men and women in four centres. BJUI 2003 september; 92(4): 409-414. |
[18] | Pintarelli, Vitor Last, Perchon, Lygia Ferreira Gomes, Lorenzetti, Fábio, TonioloNeto, João, &Dambros, Miriam. Elderly men's quality of life and lower urinary tract symptoms: an intricate relationship. International braz j urol 2011, 37(6), 758-765. |
[19] | Hammerer PG, McNeal JE, Stamey TA. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. The Journal of Urology 1995 Jan; 153: 111–114. |
[20] | Agrawal CS, Chalise PR, Bhandari BB. Correlation of prostate volume with international prostate symptom score and quality of life in men with benign prostatic hyperplasia. Nepal Medical College Journal. 2008 Jun; 10(2): 104-7. |
[21] | Kojima M, Naya Y, Inoue W, Ukimura O, Watanabe M, Saitoh M, Watanabe H. The American urological association symptom index for benign prostatic hyperplasia as a function of age, volume and ultrasonic appearance of the prostate. The Journal of Urology 1997 Jun; 157: 21-65. |
[22] | Tang P, Jin XL, Uhlman M, Lin YR, Deng XR, Wang B, Xie KJ. Prostate volume as an independent predictor of prostate cancer in men with PSA of 10–50 ng ml−1. Asian J Androl. 2013 May 6; 15(3): 409–412. |
[23] | Roehrborn CG, McConnell J, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163: 13–20. |
[24] | Asimakopoulos AD, De Nunzio C, Kocjancic E, Tubaro A, Rosier PF, Finazzi-Agro E. Measurement of post-void residual urine. Neurourol Urodyn. In press. http://dx.doi.org/10.1002/nau.22671. |
[25] | Rule AD, Jacobson DJ, McGree ME, Girman CJ, Lieber MM, Jacobsen SJ. Longitudinal changes in post-void residual and voided volume among community dwelling men. J Urol 2005; 174: 1317–21. |
[26] | Kaplan SA. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. The journal of urology.2016 December; 196(6): 1712–1714. |
[27] | Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006; 97: 734–41. |
[28] | Kolman C, Girman CJ, Jacobsen SJ, Lieber MM. Distribution of post void residual urine volume in randomly selected men. The Journal of Urology 1999 Jan. 161(1): 122–127. |
[29] | Mochtara, C A, Kiemeneyb L A L M, van Riemsdijkd C M M. Lagunaa M P, Debruyneb FMJ, de la Rosettea JJMNH. Post-Void Residual Urine Volume is Not a Good Predictor of the Need for Invasive Therapy among Patients with Benign Prostatic Hyperplasia. The Journal of Urology 2006 Jan. 175(1): 213–216. |
[30] | Berges R, Oelke M. Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older. World Journal of Urology 2011 April; 29(2): 171–178. |
[31] | Engstrom G. Lower urinary tract Symptoms in Swedish male population – prevalence, distress and quality of life. Diva-portal.org-2006. Thesis: 8485. |
[32] | Eldwo SAA, Sherfi A. Comparison between transurethral resection of the prostate and transvesivalprostatectomyin management of benign prostatic hypertrophy. Sudan specialization board MD thesis 2015. |